Amicus Therapeutics Story

Amicus Therapeutics -- USA Stock  

USD 13.78  0.22  1.57%

Macroaxis does not monitor all media channels or aggregates social signals for Amicus Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Amicus Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Amicus Therapeutics. Additionally see Amicus Therapeutics Hype Analysis, Amicus Therapeutics Correlation and Amicus Therapeutics Performance.
Acquisition by Hung Do of 29803 shares of Amicus Therapeutics subject to Rule 16b-3
Filed transaction by Amicus Therapeutics Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Amicus Therapeutics Inc insider trading alert for grant of common stock by Hung Do, Chief Science Officer, on January 3, 2018. This event was filed by Amicus Therapeutics Inc with SEC on 2018-01-05. Statement of changes in beneficial ownership - SEC Form 4. Hung Do is currently serves as senior vice president - discovery biology of Amicus Therapeutics Inc

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.47% . The overall trading delta when the story was published against the current closing price is 9.00% .

Similar stores for Amicus Therapeutics

a day ago at 
Hot Mover of the Day Amicus Therapeutics Inc
Stocks PenFull coverage
Amicus Therapeutics, Inc. trend is considered bearish as stock price is -1.16 percent declining from 50 SMAnews
Analyst Recommendation Full coverage
over two months ago at 
Hot Stock in the Spotlight Amicus Therapeutics Inc
U.S. stocks tumbled again Thursday as investors continued to fret about the possibility of rising inflation and higher interest rates.

Did you try this?

Run Pattern Recognition Now

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
View All  Next Launch Pattern Recognition

Cash Flow from Operations

Cash Flow from Operations Comparative Analysis
  Cash Flow from Operations 
      Amicus Therapeutics Comparables 
Amicus Therapeutics is currently under evaluation in cash flow from operations category among related companies. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investor or analyst to check on the quality of a company earnings.


Amicus Therapeutics Related Equities
DRNA  7.21 %   
DOVA  3.43 %   
VBLT  2.33 %   
VCEL  2.12 %   
DMTX  0.00 %   
DRRX  0.48 %   
DNLI  1.29 %   
NK  1.69 %   
DMPI  2.39 %   
VBIV  2.47 %   
Additionally see Amicus Therapeutics Hype Analysis, Amicus Therapeutics Correlation and Amicus Therapeutics Performance. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.